2024
Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatment
2023
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsionImagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study
Maloney G, Kelmendi B, Pittenger C. Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study. Clinical Case Studies 2022, 22: 174-191. DOI: 10.1177/15346501221123797.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-resistant obsessive-compulsive disorderResponse preventionOCD symptomsERP treatmentFirst-line psychological treatmentImagery rescriptingCompulsive checkingResistant obsessive-compulsive disorderPsychological treatmentSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyBehavior therapyOCD sufferersLife satisfactionInterpersonal relationshipsERPTranscript excerptsTherapy adjunctInitial researchRescriptingCognitiveFurther researchIndividualsDisordersSpecific types
2018
The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder
Adams T, Kelmendi B, Brake C, Gruner P, Badour C, Pittenger C. The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder. Chronic Stress 2018, 2: 2470547018758043. PMID: 29527593, PMCID: PMC5841259, DOI: 10.1177/2470547018758043.Peer-Reviewed Original ResearchOnset of symptomsOCD symptomatologyNeuronal hypertrophyNeuronal atrophyPathophysiological relationshipLimbic circuitsLimbic circuitryFrontal cortexDorsolateral striatumPsychosocial stressGoal-directed learningNeural abnormalitiesPsychiatric symptomatologyDorsomedial striatumPreclinical researchNonspecific factorsRole of stressSymptomsCompulsive disorderSymptomatologyStriatumOCD symptomsPathogenesisIndependent causeTraumatic incidents
2015
Meta-Analysis of the Symptom Structure of Obsessive-Compulsive Disorder
Bloch M, Landeros-Weisenberger A, Rosario M, Pittenger C, Leckman J. Meta-Analysis of the Symptom Structure of Obsessive-Compulsive Disorder. FOCUS The Journal Of Lifelong Learning In Psychiatry 2015, 13: 232-243. DOI: 10.1176/appi.focus.130209.Peer-Reviewed Original ResearchSomatic obsessionsOCD symptoms
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion